Skip to content
value.today
Fractyl Health, Inc. logo

Fractyl Health, Inc.

GUTS
$13 Mmarket cap on Oct 30, 2026
Compare
World rank
#25,361
Revenue
—
For year ending December-2025
Net income
$-141 M
SEC filing
Employees
100
As of March 1, 2026
SEC filing

Fractyl Health, Inc. in brief

Fractyl Health, Inc. is a listed company in the Healthcare sector, based in Burlington, Massachusetts, USA. Its market value was $13 M on 30 October 2026, which makes it the 25,361st largest listed company in the world and the 4,237th largest in the USA on this site. It employs about 100 people and Harith Rajagopalan is its chief executive. Its shares trade under the symbol GUTS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Fractyl Health, Inc.

We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.

Despite advances in treatment over the last 50 years, obesity and T2D continue to be principal and rapidly growing drivers of morbidity and mortality. According to the Centers for Disease Control approximately 115 million people in the U.S. have prediabetes and/or are living with obesity, and an additional approximately 27 million people have T2D and are potentially on medical therapy. Within the past two years, the unmet need in obesity has shifted rapidly from identifying treatments that can achieve short-term weight loss to identifying treatments that can enable durable weight maintenance. While highly potent drugs in the glucagon-like peptide-1 receptor agonist class are now available to lower weight and blood sugar, these agents have high discontinuation rates that lead to a substantial risk of weight and metabolic rebound. According to a Kaiser Family Foundation Health Tracking Poll from November 2025, approximately 12% of adults are taking glucagon-like peptide-1 drugs (an increase of 6 percentage points from May 2024), translating to approximately 30 million patients potentially on therapies that require chronic administration and do not correct the underlying disease of obesity. Despite the growing interest in these drugs, a Blue Health Intelligence brief from 2024 found that over 50% of patients discontinue GLP-1 drugs within three months of starting, long before patients can experience clinical benefit from these agents.

From the company's annual report filed with the US SEC: read the report

Fractyl Health, Inc. timeline

3 events, 2013–2024
  1. 2013
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. ✎
    Renamed Fractyl Health, Inc.
    Formerly Fractyl Laboratories Inc..
  5. 2024
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 2 February 2024; shares registered for exchange trading on 29 January 2024.

Events of Fractyl Health, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$29 M$58 M$87 M$117 M

World rank over time

▼ down 8,206 places since 2026
2026-08-01: #17163#17,16320262026-10-13: #20822#20,82220262026-10-30: #25369#25,3692026

Rank in USA: #3,390 (Aug 2026) · #3,771 (Oct 2026) · #4,239 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.4×
Free cash flow yield
-692.2%
Net margin
—
Operating margin
—
Return on equity
-1490.0%
Liabilities / assets
92.2%
Revenue growth
-25.0%
R&D / revenue
78300.0%
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue $0M, net income $-77M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-69M$0MFY24Fiscal year ending Dec 2025: revenue —, net income $-141M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-97M$-141M—
Dec 2024$0M-25.0%$-94M$-69M-76322.2%
Dec 2023$0M—$-51M$-77M-64241.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-90M$1M$-91M$-1.86—
Dec 2024$-66M$2M$-67M$-1.62—
Dec 2023$-43M$0M$-43M$-45.29—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-25M$0MDec ’24Three months to Mar 2025: revenue —, net income $-24M—Mar ’25Three months to Jun 2025: revenue —, net income $-28M—Jun ’25Three months to Sep 2025: revenue —, net income $-46M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-44M—Dec ’25Three months to Mar 2026: revenue —, net income $9M—Mar ’26Three months to Jun 2026: revenue —, net income $-26M—Jun ’26Three months to Sep 2026: revenue —, net income $-14M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Fractyl Health, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-97 M
Net income
$-141 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$121 M
Total liabilities
$112 M
Total equity
$9 M

As of December-2025

Top 6 institutional investors in Fractyl Health, Inc.#

As of Sep 30, 2026
6 institutions held 9.4 M shares (about 71.2% of the shares outstanding) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 13, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 6 largest institutional investors in Fractyl Health, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Nantahala Capital Management, LLC7,458,269New56.23%$4 MNov 13, 2026
2Marshall Wace, LLP1,884,135New14.20%$1 MNov 13, 2026
3Parallel Advisors, LLC47,835New0.36%$0 MNov 3, 2026
4FNY Investment Advisers, LLC35,600New0.27%$0 MOct 16, 2026
5Catalyst Funds Management Pty Ltd10,831New0.08%$0 MNov 12, 2026
6SBI Securities Co., Ltd.4,021New0.03%$0 MOct 22, 2026

Mutual funds holding Fractyl Health, Inc.#

12 funds hold shares worth $6 M (about 4.6% of the company). Since their previous reports 5 added shares and 5 sold, buying $0 M net.
Mutual funds holding Fractyl Health, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.4.62 M$4 M2.9%<0.01%+12%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.25 M$1 M0.79%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC594,704$0 M0.38%<0.01%+13%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC214,366$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC181,077$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.149,625$0 M0.10%<0.01%+945%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC104,682$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.71,631$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.67,750$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.15,009$0 M<0.01%<0.01%+18%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC10,500$0 M<0.01%<0.01%−3.7%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC3,247$0 M<0.01%<0.01%+33%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Fractyl Health, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$187 K
7 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$187 K
open market only
Insiders on file
19
since
$12.0 M-$397 K$0Feb 2024: bought $12.0 M (4 trades), sold $0 (0 trades)Feb 24Sep 2024: bought $0 (0 trades), sold $189 K (1 trades)SepNov 2024: bought $0 (0 trades), sold $397 K (2 trades)NovJan 2025: bought $0 (0 trades), sold $289 K (4 trades)Jan 25Mar 2025: bought $94 K (5 trades), sold $0 (0 trades)MarDec 2025: bought $20 K (1 trades), sold $0 (0 trades)DecJun 2026: bought $127 K (5 trades), sold $0 (0 trades)JunSep 2026: bought $40 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Fractyl Health, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed William BradleyDirectorBuy+64,516$0.620$40 K149,138Form 4
filed Ajay RoyanDirectorBuy+23,000$0.850$20 K40,901Form 4
filed William BradleyDirectorBuy+68,493$0.730$50 K84,622Form 4
filed Harith RajagopalanChief Executive Officer, DirectorBuy+25,000$0.730$18 K540,557Form 4
filed Ian SheffieldDirectorBuy+35,000$0.730$26 K35,000Form 4
filed Weber Lara SmithChief Financial OfficerBuy+20,000$0.690$14 K20,000Form 4
filed Harith RajagopalanChief Executive Officer, DirectorBuy+10,416$1.920$20 K501,745Form 4
filed Ajay RoyanDirector, 10% ownerBuy+17,901$1.280$23 K17,901Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Fractyl Health, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
585,071
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 12-for-1 split ; 1-for-2.15 reverse split

Trading halts

  • 2026-10-02 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 30,589 shares at $0.99
  • : 69 shares at $1.33
  • : 84 shares at $1.55
  • : 122 shares at $4.08
  • : 83 shares at $4.41

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Fractyl Health, Inc. scorecard#

Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Healthcare's median of 3.1×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.86 vs -1.62Diluted EPS -1.86 in fiscal 2025 against -1.62 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$141 MNet income -$141 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-744.2%-744.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.8×Current ratio 4.78 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year74.1%Diluted shares up 74.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Fractyl Health, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Fractyl Health, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Revenue00.10.1
Cost of revenue00.10.1
Gross profit—0.00.0
Research and development757038
Selling, general and administrative222313
Operating expenses979451
Operating income−97−94−51
Interest and finance income1.54.11.3
Other non-operating income (expense)−4425−26
Income tax000
Net income including minority interests−141−69−77
Net income attributable to shareholders−141−69−77
Earnings per share, basic-1.86-1.62-45.29
Earnings per share, diluted-1.86-1.62-45.29
Shares, weighted average (basic)76442.1
Shares, weighted average (diluted)76442.1
Balance sheet
Cash and cash equivalents826733
Receivables—00.0
Inventory—0.10.1
Other current assets6.0——
Current assets887236
Property, plant and equipment2.43.00.5
Right-of-use (leased) assets272830
Total assets12110876
Accounts payable1.63.20.6
Current liabilities182011
Lease liabilities (non-current)262729
Total liabilities11280114
Retained earnings−556−415−347
Shareholders' equity9.528−325
Total liabilities and equity12110876
Shares outstanding13r492.1
Cash-flow statement
Share-based compensation6.7144.3
Cash from operating activities−90−66−43
Capital expenditure−0.6−1.8−0.4
Cash from investing activities−0.6−1.8−0.4
Shares issued6.8——
Cash from financing activities10510127
Change in cash1434−16
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Fractyl Health, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 1 · Directors and officers 4 · Material agreement 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 7

Fractyl Health, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
RestructuringDirectors and officers8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of Fractyl Health, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$100 MNo. 6$50 to $250 million15equitySEC
Mar 2020$45 MNo. 5$10 to $50 million15equitySEC
Jun 2017$44 MNo. 4$10 to $50 million19equitySEC
Oct 2015$47 MNo. 3$10 to $50 million16equitySEC
Aug 2014$20 MNo. 2$10 to $50 million13equitySEC
Mar 2013$14 MNo. 1$10 to $50 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Fractyl Health, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $143 K a year.

Certified, FY2026
1
#1,952 among companies on value.today
Worker positions
1
Median wage offered
$143 K
a year, full-time
Applications filed
1
Fractyl Health, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Manager, Regulatory AffairsRegulatory Affairs Specialists1$143 K

Where: Burlington, MA 1

Fractyl Health, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$143 K1
FY202422$115 K2
FY202311$125 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Fractyl Health, Inc.

Layoffs at Fractyl Health, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
22
2025–2026
Latest
—
2026-10-21
Fractyl Health, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
202522···········22
Fractyl Health, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
45% of workforceRestructuring planSEC 8-K“As part of the plan, the Company will reduce its workforce by approximately 45% of the Company’s current headcount.”Filing
22 people (17% of workforce)Restructuring planSEC 8-K“As part of the Strategic Reprioritization, the Company is streamlining resources, including a workforce reduction impacting 22 employees, or approximately 17% of the Company’s work…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Fractyl Health, Inc. compares in Healthcare

  • Market cap$13 M · higher than 9% of 2,013
  • Revenue growth-25.0% · higher than 16% of 1,003
  • Price / book1.4× · lower than 73% of 1,245
CompanyMarket capP/ENet marginRev. growth
Fractyl Health, Inc.🇺🇸$13 M——-25.0%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Fractyl Health, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Fractyl Health, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Fractyl Health, Inc.? Suggest a correction